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Abstract: Primary liver cancer comprises a diverse group of liver tumors. The heterogeneity of
these tumors is seen as one of the obstacles to finding an effective therapy. The Hippo pathway,
with its downstream transcriptional co-activator Yes-associated protein (YAP) and transcriptional
co-activator with PDZ-binding motif (TAZ), has a decisive role in the carcinogenesis of primary
liver cancer. Therefore, we examined the expression pattern of YAP and TAZ in 141 patients
with hepatocellular carcinoma keratin 19 positive (HCC K19+), hepatocellular carcinoma keratin
19 negative (HCC K19−), combined hepatocellular–cholangiocarcinoma carcinoma (cHCC-CCA),
or cholangiocarcinoma (CCA). All cHCC-CCA and CCA patients showed high expression levels
for YAP and TAZ, while only some patients of the HCC group were positive. Notably, we found
that a histoscore of both markers is useful in the challenging diagnosis of cHCC-CCA. In addition,
positivity for YAP and TAZ was observed in the hepatocellular and cholangiocellular components
of cHCC-CCA, which suggests a single cell origin in cHCC-CCA. Within the K19− HCC group,
our results demonstrate that the expression of YAP is a statistically significant predictor of poor
prognosis when observed in the cytoplasm. Nuclear expression of TAZ is an even more specific and
independent predictor of poor disease-free survival and overall survival of K19− HCC patients. Our
results thus identify different levels of YAP/TAZ expression in various liver cancers that can be used
for diagnostics.
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1. Introduction
Hepatocellular carcinoma (HCC) incidence rates have been increasing for the last couple of
decades [1]. Primary liver cancer (PLC) is the second most common cause of cancer-related deaths
worldwide. The most frequent risk factors worldwide are hepatitis B virus (HBV) and chronic hepatitis
C virus (HCV) infection, which lead up to cirrhosis and, eventually, HCC. Furthermore, the prevalence
of non-alcoholic fatty liver disease (NAFLD) is increasing dramatically and is known to be an important
risk factor for HCC [2,3]. It is suggested that NAFLD may soon overtake HBV and HCV as most
common etiology of HCC [4]. However, the majority of studies into the carcinogenesis of HCC use
cohorts of patients that are dominated by a viral-induced liver disease in the background, while other
etiologies are not sufficiently represented.
A very fascinating group of PLC is the combined (or mixed) hepatocellular–cholangiocarcinoma
(cHCC-CCA), which presents mixed characteristics of HCC and cholangiocarcinoma (CCA) in one
tumor. This dual morphology and recent molecular findings suggest that the cell of origin of these
tumors is the hepatic progenitor cell (HPC) [5–7]. However, despite many decades of research on
cHCC-CCA, there is a marked lack of a consensus in the terminology used to describe these tumors.
This is due to a high degree of intratumoral heterogeneity in cHCC-CCA tumors [8]. For this reason, an
international platform of experts has agreed upon a pathological description of this tumor subgroup.
The internationally accepted description of cHCC-CCA provides the opportunity for more in-depth
investigation of these rare tumors of possible HPC-derived origin [8]. In addition, we and others have
demonstrated the existence of a subgroup of keratin 19 positive (K19+) HCCs within the group of HCCs.
These K19+ HCCs are more aggressive than keratin 19 negative (K19−) HCCs [9–13]. Therefore, liver
cancer is a highly heterogeneous disease, and understanding the molecular pathways governing this
heterogeneity is crucial for the development of effective therapeutic approaches against the different
subtypes of liver cancer [14].
The Hippo signaling pathway is a signal transduction pathway that plays important roles in
the regulation of organ growth, cell proliferation, and cellular plasticity [15–17]. In recent years,
the Hippo pathway has attracted a lot of attention because it is deregulated in most human cancers
and can trigger tumorigenesis in experimental mouse models [18,19]. The core of the Hippo pathway
comprises a kinase cascade of the STE20-like protein kinases (MST1/2), and the Large tumor suppressor
kinases (LATS1/2), which phosphorylate and repress the activity of the transcriptional co-activators
Yes-associated protein 1 (YAP) and its homolog WW domain-containing transcription regulator protein
1 (WWTR1, also called TAZ) [20]. Phosphorylated YAP and TAZ are retained in the cytoplasm and
targeted for proteasomal degradation, while non-phosphorylated YAP/TAZ can enter the nucleus
and bind to the TEA Domain Transcription Factors (TEAD 1–4) to regulate target gene expression [21].
Although YAP and TAZ play highly redundant roles, there is some emerging evidence suggesting that
they might have different functions in primary liver cancer [22]. However, little is known about their
function in primary liver cancer and how they contribute to the development of the different subtypes
of liver tumors. Thus, we aimed to investigate the expression of YAP and TAZ in a cohort of Caucasian
primary liver patients in a mainly non-viral setting. We explored YAP and TAZ with interest in their
subcellular localization and prognostic significance.
2. Results
2.1. General Clinicopathological Characteristics of HCC, cHCC-CCA, and CCA Patients
For our studies, we analyzed a cohort of PLC patients treated at the University Hospitals of
Leuven. This cohort included 81 K19− HCC, 13 K19+ HCC, 35 cHCC-CCA, and 12 CCA patients. First,
we defined the clinicopathological characteristics of each subtype of PLC (Table 1). In the HCC group,
we found that the K19+ carcinomas presented more vascular invasive characteristics compared to the
K19− group (p = 0.014). Moreover, cHCC-CCA demonstrated features of a more aggressive behavior
such as an increased tumor diameter, vascular invasion, and higher proliferation index (p = 0.009,
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p = 0.002, and p < 0.001) compared to K19− HCC. Additionally, cHCC-CCA showed a predominance
in females, non-viral-infected, and non-cirrhotic livers when compared to HCC K19− (respectively,
p = 0.006, p = 0.007, and p < 0.001). Importantly, as part of the clinical work-up, all cHCC-CCA tumors
(100%; 35/35) showed positivity for K19 (Figure 1). In the CCA group, no cirrhotic background or
viral disease was observed in the corresponding livers. The CCA lesions were more often singular
(p = 0.008), had a higher proliferation index (p ≤ 0.001), and showed prominent vascular invasion
(p = 0.002) compared to the K19− HCC. This analysis reveals increasing aggressiveness from K19− HCC
to K19+ HCC, over cHCC-CCA, to CCA. This axis also reflects increasing cholangiocytic characteristics.
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Figure 1. Representative immunohistochemistry images of YAP, TAZ, Keratin 19 (K19) is shown for hepatocellular 
carcinoma (HCC) K19−, HCC K19+, combined hepatocellular–cholangiocarcinoma (cHCC-CCA), and 
cholangiocarcinoma (CCA) cases. The spectrum of HCC Keratin 19− is illustrated by a case that shows the absence of 
YAP and TAZ in the tumor cells, while another case of HCC Keratin 19− illustrates high expression of YAP and TAZ. 
HCC K19+ is represented by a case that has high YAP and TAZ expression. The hepatocellular and cholangiocellular 
components show expression in the cytoplasm and nucleus. CCA shows positivity for YAP and TAZ. All images were 
taken at 20×. Scale bar: 100 µm. 
2.2. Increased Levels of YAP/TAZ as a Defining Marker in cHCC-CCA and CCA versus HCC Patients 
To understand the correlation between YAP and TAZ expression and the different subtypes of 
liver cancer, we evaluated their expression in K19-negative HCCs, K19-positive HCCs, cHCC-CCA, 
and CCA (Table 1). We observed several cases with only the cytoplasmic presence of YAP and TAZ, 
while other cases showed a combination of both nuclear and cytoplasmic localization (Figure 1). No 
cases showed only nuclear expression without the presence of a cytoplasmic staining. A detailed 
analysis of the cytoplasmic and nuclear presence of YAP and TAZ (Table 1) showed increasing levels 
of nuclear accumulation along the HCC–CCA axis. In the K19− HCC cases, 81% (66/81) were positive 
for YAP in the cytoplasm and 64% (52/81) showed nuclear YAP, while 58% (47/81) and 21% (17/81) 
had cytoplasmic and nuclear TAZ, respectively. The K19+ HCC cases showed higher levels of YAP in 
the cytoplasm (92%) and nucleus (77%) compared to K19-negative cases. Comparable localization 
patterns were observed for TAZ: K19+ HCC and K19− HCC had an almost similar incidence of 
cytoplasmic TAZ positivity (54% vs. 58%), and a higher incidence of nuclear TAZ positivity in K19+ 
compared to K19− HCC was noted (38% vs. 21%). All cHCC-CCA and CCA showed high levels of 
TAZ and YAP in the cytoplasm and nucleus. No microscopic differences were observed between the 
hepatic and cholangiocytic components in cHCC-CCA (Figure 1).  
Notably, the localization pattern of YAP and TAZ was very heterogeneous in multiple cases, 
especially in the HCC (K19− and +) group; that is, while some parts of the tumor were completely 
negative, others were strongly positive (Figure 2). Therefore, we used the histoscore (H-score) to 
evaluate the intensity and area of YAP/TAZ expression in tumor cells (Figure 2). Notably, this 
analysis revealed that the H-score of YAP and TAZ in the cytoplasm of the HCC groups was 
significantly lower compared to those of the cHCC-CCA and CCA groups (p < 0.001 and p < 0.001) 
(Figure 2). Analogous results were seen when the nuclear presence of YAP and TAZ was scored and 
Figure 1. Repres t tive immunohistochemistry images of Y P, TAZ, Keratin 19 (K19) is shown for
hepatocellular carcinoma (HCC) K19−, HCC K19+, combined hepatocellular–cholangiocarcinoma
(cHCC-CCA), and cholangiocarcinoma (CCA) cases. The spectrum of HCC Keratin 19− is illustrated
by a case that shows the absence of YAP and TAZ in the tumor cells, while another case of HCC Keratin
19− illustrates high expression of YAP nd TAZ. HCC K19+ is represented by a case that has high YAP
and TAZ expression. The hepatocellular and cholangiocellular components show expression in the
cytoplasm and nucleus. CCA shows positivity for YAP and TAZ. All images were taken at 20×. Scale
bar: 100 µm.
2.2. Increased Levels of YAP/TAZ as a Defining Marker in cHCC-CCA and CCA versus HCC Patients
To understand the correlation between YAP and TAZ expression and the different subtypes of
liver cancer, we evaluate their expression in K19-negative HCCs, K19-positive HCCs, cHCC-CCA,
and CCA (Table 1). We observed several cases with only the cytoplasmic presence of YAP and TAZ,
while other cases showed a combination of both nuclear and cytopl smic localization (Figure 1). No
cases showed only nucle r expression without the presence of a cytoplasmic staining. A deta led
analysis of the cytoplasmic nuclear presence of YAP and T Z (Tabl 1) showed increasing levels of
nuclear accumulation along the HCC–CCA axis. In the K19− HCC cases, 81% (66/81) were positive for
YAP in the cytoplasm 64% (52/81) showed nuclear YAP, while 58% (47/81) and 21% (17/81) had
cytoplasmic and nuclear TAZ, respectively. The K19+ HCC cases showed higher levels of YAP in the
cytoplasm (92%) and nucleus (77 ) compared to K19-n gative cas s. Comparable localization patterns
were observed for TAZ: K19+ HCC and K19− HCC had an almost similar incidence of cytopla mic
TAZ positivity (54% vs. 58%), and a high r incidence f nuclear TAZ positivity in K19+ compared to
K19− HCC was noted (38% vs. 21%). All cHC -C A and CCA showed high levels of TAZ and YAP
in the cytoplasm and nucleus. No microscopic differences were observed betwee the hepatic and
cholangiocytic components in cHCC-CCA (Figure 1).
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Table 1. Clinicopathological characteristics.
Characteristics HCC (K19
−)
(n = 81)
HCC (K19+)
(n = 13)
cHCC-CCA
(n = 35) CCA (n = 12)
HCC (K19−)
vs.
HCC (K19+)
HCC (K19−)
vs.
cHCC-CCA
HCC (K19+)
vs.
cHCC-CCA
HCC (K19−)
vs.
CCA
Age (mean ± SD), years 61.3 ± 11.7 64.0 ± 8.9 64.5 ± 9.5 61 ± 11.0 0.528 0.21 0.829 0.703
Sex
1 0.006 0.193 0.35Male 58 (72%) 9 (69%) 15 (43%) 7 (58%)
Female 23 (28%) 4 (31%) 20 (57%) 5 (42%)
Etiology
1 0.007 0.187 0.014Viral 29 (36%) 4 (31%) 4 (11%) 0 (0%)
Non-viral * 52 (64%) 9 (69%) 31 (89%) 12 (100%)
Tumor diameter (mm)
0.369 0.002 0.321 0.564< 50 mm 54 (67%) 7 (54%) 12 (34%) 9 (75%)
≥ 50 mm 27 (33%) 6 (46%) 23 (66%) 3 (25%)
Differentiation grade
0.469 0.895 0.368 0.905
Well 12 (15%) 1 (8%) 6 (17%) 3 (25%)
Moderate 50 (62%) 7 (54%) 22 (63%) 7 (58%)
Poorly 19 (23%) 5 (38%) 7 (20%) 2 (17%)
Number of nodules
0.553 0.008 0.018 0.008Single 41 (51%) 5 (38%) 27 (77%) 11 (92%)
Multiple 40 (49%) 8 (62%) 8 (23%) 1 (8%)
Vascular invasion
0.014 0.009 0.469 0.002Present 36 (44%) 11 (85%) 25 (71%) 11 (92%)
Absent 45 (56%) 2 (15%) 10 (29%) 1 (8%)
Cirrhotic background
1 <0.001 <0.001 <0.001Present 58 (72%) 10 (77%) 5 (14%) 0 (0%)
Absent 23 (28%) 3 (23%) 30 (86%) 12 (100%)
Proliferation (Ki67+)
1 <0.001 0.011 <0.001Low 63 (78%) 10 (77%) 12 (34%) 2 (17%)
High 18 (22%) 3 (23%) 23 (66%) 10 (83%)
YAP cytoplasmic
0.452 0.005 0.271 N/APresent 66 (81%) 12 (92%) 35 (100%) 12 (100%)
Absent 15 (19%) 1 (8%) 0 (0%) 0 (0%)
Int. J. Mol. Sci. 2019, 20, 638 5 of 17
Table 1. Cont.
Characteristics HCC (K19
−)
(n = 81)
HCC (K19+)
(n = 13)
cHCC-CCA
(n = 35) CCA (n = 12)
HCC (K19−)
vs.
HCC (K19+)
HCC (K19−)
vs.
cHCC-CCA
HCC (K19+)
vs.
cHCC-CCA
HCC (K19−)
vs.
CCA
YAP nuclear
0.531 <0.001 0.017 N/APresent 52 (64%) 10 (77%) 35 (100%) 12 (100%)
Absent 29 (36%) 3 (23%) 0 (0%) 0 (0%)
TAZ cytoplasmic
0.773 <0.001 <0.001 N/APresent 47 (58%) 7 (54%) 35 (100%) 12 (100%)
Absent 34 (42%) 6 (46%) 0 (0%) 0 (0%)
TAZ nuclear
0.175 <0.001 <0.001 N/APresent 17 (21%) 5 (38%) 35 (100%) 12 (100%)
Absent 64 (79%) 8 (62%) 0 (0%) 0 (0%)
* Non-viral background in HCC (K19−) patients was related to alcoholic steatohepatitis (ASH) (n = 21), non-alcoholic steatohepatitis (NASH) (n = 15), hemochromatosis (n = 3), PBC
(n = 1), glycogen storage disease (n = 1), Wilson’s disease (n = 1), and cryptogenic (n = 10). For HCC (K19+) patients this was related to ASH (n = 4), NASH (n = 4), and hemochromatosis
(n = 1). For cHCC-CCA patients this was related to ASH (n = 2) and Wilson’s disease (n = 1), and all other cases had no known chronic liver disease. SD, standard deviation.
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Notably, the localization pattern of YAP and TAZ was very heterogeneous in multiple cases,
especially in the HCC (K19− and +) group; that is, while some parts of the tumor were completely
negative, others were strongly positive (Figure 2). Therefore, we used the histoscore (H-score) to
evaluate the intensity and area of YAP/TAZ expression in tumor cells (Figure 2). Notably, this analysis
revealed that the H-score of YAP and TAZ in the cytoplasm of the HCC groups was significantly lower
compared to those of the cHCC-CCA and CCA groups (p < 0.001 and p < 0.001) (Figure 2). Analogous
results were seen when the nuclear presence of YAP and TAZ was scored and compared between HCC
and cHCC-CCA (p < 0.001 and p < 0.001). To conclude, our immunohistochemical analysis showed an
increasing YAP/TAZ positivity along the HCC–CCA axis.
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Figure 2. The histoscores (H-scores) of HCC K19−, HCC K19+, cHCC-CCA, and CCA were plotted (A).
Statistically significant differences in YAP and TAZ expression in the cytoplasm and nucleus were
observed between the HCC groups, cHCC-CCA, and CCA (*** p < 0.001). Intratumoral heterogeneity
is illustrated in a representativ example of an HCC K19- case (B). Regions with and without YAP and
TAZ were observed in this case. Expression of YAP and TAZ in all compartments of the biliary tree
was observed (C). Illustration of two HCC cases with a low and high proliferation index (Ki-67) (D).
All images were taken at 20×. Scale bar: 100 µm.
2.3. Co-Expression Profile of YAP and TAZ
In the K19− HCC group, the cytoplasmic presence of YAP was always together with nuclear
positivity (Table 2). In addition, positivity of TAZ in the nucleus of K19− HCC was accompanied by
positivity of YAP in the nucleus in 94% (16/17) of the cases. Additionally, we scored the co-expression
of YAP and TAZ. We found that 31% (16/52) of the YAP-positive K19− HCCs were also positive for
TAZ and, conversely, that 94% (16/17) of TAZ-positive K19− HCCs were also positive for YAP (Table 2).
In the K19+ HCC group, which was too small to obtain statistically significant results, similar ratios of
YAP/TAZ as i the K19− HCC group were observed (Table 2). YAP and TAZ were broadly expressed
in all cases of the cHCC-CCA and CCA groups, for both cytoplasmic and nuclear presence (Figure 2
and Table 2).
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Table 2. Clinicopathological characteristics in relation to YAP and TAZ expression.
HCC (K19−) HCC (K19+) cHCC-CCA CCA
YAP
Nuclear
+/−
(n = 52/29)
p
TAZ
Nuclear
+/−
(n = 17/64)
p
YAP
Nuclear
+/−
(n = 10/3)
p
TAZ
Nuclear
+/−
(n = 4/8)
p
YAP or TAZ
Nuclear
+/−
(n = 35/0)
YAP or TAZ
Nuclear
+/−
(n = 12/0)
Age (years)
0.035 0.202 1.0 1.0<65 25/7 9/23 3/1 1/3 24/0 7/0
≥65 27/22 8/41 7/2 3/5 11/0 5/0
Sex
0.694 0.478 1.0 1.0Male 38/20 11/47 7/2 3/5 15/0 7/0
Female 14/9 6/17 3/1 1/3 20/0 5/0
Etiology
0.102 0.026 0.203 1.0Viral 22/7 10/19 2/2 1/3 4/0 0/0
Non-viral 30/22 7/45 8/1 3/5 31/0 12/0
Tumor diameter (mm)
0.743 0.177 0.192 1.0<50 mm 18/9 8/19 6/0 2/3 23/0 9/0
≥50 mm 34/20 9/45 4/3 2/5 12/0 3/0
Differentiation grade
0.503 0.341 0.70 0.13
Well 6/6 3/9 0/1 0/1 6/0 3/0
Moderate 34/16 8/42 4/1 1/6 22/0 7/0
Poorly 12/7 6/13 5/3 3/1 7/0 2/0
Differentiation grade
0.503 0.341 0.70 0.13
Well 6/6 3/9 0/1 0/1 6/0 3/0
Moderate 34/16 8/42 4/1 1/6 22/0 7/0
Poorly 12/7 6/13 5/3 3/1 7/0 2/0
Number of tumor nodules
0.436 0.064 0.231 0.208Single 24/16 5/35 5/3 4/4 8/0 11/0
Multiple 28/13 12/29 5/0 0/4 27/0 1/0
Vascular invasion
0.604 0.059 1.0 1.0Present 22/14 11/25 8/3 4/7 25/0 11/0
Absent 30/15 6/39 2/0 0/1 10/0 1/0
Cirrhotic background
0.251 0.191 0.528 1.0Present 35/23 9/49 7/3 3/7 5/0 0/0
Absent 17/6 6/15 3/0 1/1 30/0 12/0
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Table 2. Cont.
HCC (K19−) HCC (K19+) cHCC-CCA CCA
YAP
Nuclear
+/−
(n = 52/29)
p
TAZ
Nuclear
+/−
(n = 17/64)
p
YAP
Nuclear
+/−
(n = 10/3)
p
TAZ
Nuclear
+/−
(n = 4/8)
p
YAP or TAZ
Nuclear
+/−
(n = 35/0)
YAP or TAZ
Nuclear
+/−
(n = 12/0)
Proliferation index (Ki67+)
<0.001 0.006 0.528 1.0Low 34/29 9/54 7/3 3/6 12/0 2/0
High 18/0 8/10 3/0 1/2 23/0 12/0
YAP cytoplasmic positivity
< 0.001 0.027 0.230 1.0Present 52/14 17/49 10/2 4/7 35/0 12/0
Absent 0/15 0/15 0/1 0/1 0/0 0/0
YAP nuclear positivity
N/A N/A 0.004 N/A N/A 1.0 N/A N/APresent 16/36 3/6
Absent 1/28 1/2
TAZ cytoplasmic positivity
<0.001 1.0 0.061Present 36/11 17/30 6/1 4/2 35/0 12/0
Absent 16/18 0/34 4/2 0/6 0/0 0/0
TAZ nuclear positivity
0.003 N/A N/A 1.0 N/A N/A N/APresent 16/1 3/1 4/0
Absent 36/28 6/2 0/8
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2.4. Correlation of YAP and TAZ Expression with Clinicopathological Parameters
We evaluated the pathological parameters in accordance to YAP and TAZ nuclear localization
and found a significant association between a higher proliferation index of the tumor and the
nuclear presence of YAP and TAZ (p < 0.001 and p < 0.001) in the K19− HCC cases (Table 2 and
Figure 2). Interestingly, a non-viral background was more often associated with absence of nuclear
TAZ (p = 0.026). The proliferation index (Ki-67) was significantly higher in YAP-nuclear-positive
HCCs (18/52) compared to YAP-nuclear-negative cases, which all had a low proliferative status. Other
clinicopathological parameters showed no statistically significant association with YAP or TAZ status.
Another pathological observation was strong nuclear and cytoplasmic expression of YAP and TAZ in
the ductular reaction, which contains the hepatic progenitor cells (Figure 2). The expression pattern is
reminiscent of the high expression in the normal intra- and extrahepatic bile ducts of the biliary tree.
2.5. Clinical Relevance of Nuclear and Cytoplasmic Presence of YAP and TAZ
To evaluate the prognostic significance of YAP and TAZ expression, we examined the
Kaplan–Meier curves for disease-free survival (DFS) and overall survival (OS) of patient cohorts
with or without YAP and TAZ in the nucleus and cytoplasm. HCC K19− cases had better DFS and
OS compared to K19+ cases, while cHCC-CCA had an even worse prognosis compared to the HCC
(K19+/−) group. CCA patients had the worst prognosis of all included groups (Figure 3). Since all of
the cHCC-CCA and CCA patients had high YAP and TAZ expression, their expression status cannot
differentiate prognosis for these groups. However, we further evaluated the K19-negative group
because this group showed heterogeneous expression of YAP/TAZ. The K19-positive group was too
small to be statistically relevant. To appraise the relevance of nuclear versus cytoplasmic localization
of YAP and TAZ, we divided the HCC K19− cohort into three subgroups. The first subgroup was cases
which had nuclear and cytoplasmic YAP. The second subgroup was the cases that had cytoplasmic
but not nuclear YAP. The third subgroup contained the cases without any positive YAP staining in
the nucleus or cytoplasm. The same subdivision was made for TAZ expression. As mentioned above,
no cases were solely positive in the nucleus. These nuclear-positive cases were always accompanied
by cytoplasmic positivity. Disease-free survival and overall survival analysis showed no statistical
difference between the three subgroups when YAP was taken into account, although there was a
trend towards a less favorable prognosis when YAP was present in the nucleus and/or cytoplasm
(Figure 3). On the other hand, positivity for TAZ in the cytoplasm did not seem to influence the DFS or
OS. However, cases with nuclear TAZ had significantly poorer DFS and OS of (p = 0.006 and p = 0.001).
In the overall univariate analysis of the HCC K19− patients, a histologically observed tumor size
greater than 50 mm (p < 0.001) and lymphovascular invasion (p < 0.001) were significantly related with
a greater chance of recurrence and correspondingly less favorable overall survival (Table 3). Univariate
analysis demonstrated the prognostic importance of nuclear localization of TAZ for DFS and OS in
HCC K19− patients (p = 0.011 and p = 0.005). In a multivariate analysis, we included the significant
factors associated with a poor DFS and OS. To evaluate YAP and TAZ separately, since their presence
is strongly correlated, we performed multivariate Cox regression analysis on both (Table 3). These
findings were examined in two multivariate Cox regression models. This analysis revealed that the
presence of YAP in the cytoplasm was a significant predictor of poor overall survival for HCC K19−
patients (p = 0.022, HR: 4.395, 95% CI: 1.235–15.637) (Table 3). YAP nuclear positivity revealed a trend
but did not turn out to be a statistically significant predictor of poor survival (p = 0.063, HR: 2.823, 95%
CI: 0.946–8.424). In the second multivariate model, we observed a significant prognostic importance of
TAZ for recurrence and overall survival of the patient when TAZ was present in the nucleus (p = 0.043
and p = 0.009).
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Table 3. Univariate and multivariate analysis for overall survival and disease-free survival in HCC K19−.
Clinicopathological Characteristics DFS OS
Numbers HR (95% CI) p HR (95% CI) p
Univariate Cox Regression Analysis
Sex: male vs. female 58/23 0.996 (0.461–2.154) 0.992 0.952 (0440–2.059) 0.901
Age: ≥65 years vs. <65 years 32/49 1.312 (0.652–2.641) 0.447 1.617 (0.803–3.255) 0.178
Histological differentiation grade: well 12 1 1
Histological differentiation grade: moderately 50 0.668 (0.242–1.839) 0.435 0.725 (0.261–2.017) 0.538
Histological differentiation grade: poorly 19 1.957 (0.688–5.571) 0.208 2.316 (0.824–6.515) 0.111
Diameter: ≥50 mm vs. <50 mm 54/27 5.794 (2.778-12.086) <0.001 5.046 (2.428–10.489) <0.001
Lymphovascular invasion: present vs. absent 36/45 3.534 (1.696–7.364) 0.001 3.867 (1.844–8.110) <0.001
Multiple noduli: present vs. absent 41/40 1.268 (0.633–2.540) 0.503 1.153 (0.576–2.311) 0.687
Proliferation index: high vs. low 18/63 1.672 (0.773–3.617) 0.192 1.630 (0.753–3.529) 0.215
Viral background: present vs. absent 29/54 0.914 (0.440–1.897) 0.809 1.031 (0.495–2.144) 0.936
YAP cytoplasmic: present vs. absent 66/15 1.748 (0.613–4.985) 0.297 2.133 (0.746–6.102) 0.158
YAP nuclear: present vs. absent 52/29 1.093 (0.527–2.267) 0.811 1.212 (0.583–2.519) 0.606
TAZ cytoplasmic: present vs. absent 47/34 1.496 (0.721–3.104) 0.280 1.654 (0.795–3.444) 0.178
TAZ nuclear: present vs. absent 17/46 2.590 (1.247–5.380) 0.011 2.880 (1.372–6.042) 0.005
Multivariate Cox regression analysis
Model 1
Diameter: ≥50 mm vs. <50 mm 4.709 (2.151–10.307) <0.001 3.908 (1.759–8.679) 0.001
Lymphovascular invasion: present vs. absent 2.243 (1.019–4.963) 0.045 2.624 (1.165–5.909) 0.020
YAP nuclear− cytoplasm− 1 1
YAP nuclear− cytoplasm+ 2.622 (0.759–9.054) 0.127 4.395 (1.235–15.637) 0.022
YAP nuclear+ cytoplasm+ 1.705 (0.578–5.028) 0.333 2.823 (0.946–8.424) 0.063
Model 2
Diameter: ≥50 mm vs. <50 mm 4.408 (2.048–9.489) <0.001 3.787 (1.734–8.272) 0.001
Lymphovascular invasion: present vs. absent 2.604 (1.135–5.974) 0.024 3.027 (1.252–7.321) 0.014
TAZ nuclear− cytoplasm− 1 1
TAZ nuclear− cytoplasm+ 1.827 (0.717–4.652) 0.207 2.608 (0.971–7.005) 0.057
TAZ nuclear+ cytoplasm+ 2.396 (1.029–5.580) 0.043 3.123 (1.332–7.319) 0.009
DFS, disease free survival; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval.
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3. Discussion
Currently, clinical pathologists lack clear and easy-to-use immunohistochemical markers for the
pathological diagnosis of cHCC-CCA [8]. This tumor group expresses stemness markers and has
morphological hepatocellular as well as cholangiocellular characteristics mixed within the same tumor.
The recent consensus of international experts is therefore solely based on hematoxylin and eosin
staining (H&E) with respect to the morphological combined characteristics of the tumor. Markers like
Hepatocyte Paraffin 1, arginase-1, and canalicular staining of polyclonal carcinoembryonic antigen
(pCEA) are used as hepatocellular markers, while Keratin 7 and Keratin 19 are used to identify the
cholangiocytic component. Expression of these markers in the corresponding compartment can help
the clinical pathologist. However, the expression of these markers can change during carcinogenesis
and become difficult to interpret, and there is a lack of a specific marker for cHCC-CCA. We observed
high expression of YAP and TAZ in all cHCC-CCA compared to HCC (K19+/−). Additionally, no
differences in the expression of YAP and TAZ were observed between the hepatic and cholangiocytic
components. Our results on YAP expression are supported by similar findings in another study [16].
Therefore, we propose YAP and TAZ as helpful markers for a more accurate diagnosis of cHCC-CCA.
Primary liver cancer comprises a diverse group of carcinomas. Intertumoral and intratumoral
heterogeneity is seen as one of the difficulties in finding an effective therapy. Within the group of
HCC, it is widely supported and demonstrated that there is a distinguishable subgroup of HCC, which
is categorized as K19+ HCC [10]. These K19+ HCCs have a hepatocellular morphology and express
stemness markers, of which K19 is the best studied and evaluated [10–12]. In our study, we observed a
slight increase in YAP/TAZ expression in K19+ HCC compared to K19− HCC, although the number
of K19+ HCC cases was too few to draw statistically significant conclusions or to perform a survival
analysis. However, it is clear that the K19+ group is more aggressive compared to the K19− group.
Nevertheless, we currently do not know whether and how tumor aggressiveness is influenced by
YAP/TAZ.
The cell of origin for cHCC-CCA is not known, but there is increasing evidence implying
that hepatic progenitor cells are the cells of origin of this tumor [6,23]. A stemness origin was
recently indicated by a thorough genomic study of cHCC-CCA cases, which revealed that cHCC-CCA
has a common cell lineage for the HCC and CCA component [6]. Here we found high YAP and
TAZ expression in both components of cHCC-CCA and also in ductular reactions. The ductular
compartment is known to harbor hepatic progenitor cells in different human liver diseases. In addition,
YAP and TAZ are active in cancer stem cells and are required for their expansion [24–26]. Altogether,
these results suggest the existence of a hepatic progenitor cell as the cell of origin for cHCC-CCA.
YAP and TAZ are strongly associated with the specification and maturation of cholangiocytes in
the mouse. In addition, they are crucial for the integrity and maintenance of ductular cells and for the
expansion of this compartment [27,28]. Analogously, YAP/TAZ are also expressed at high levels in the
extra- and intrahepatic compartments of the biliary tree in the human liver. Moreover, recent studies in
the mouse highlight the importance of the YAP/TAZ–Notch interplay within the liver [29,30]. At the
same time, our previous and more recent work showed that the Notch signaling axis is critical for
biliary regeneration through mobilization of the hepatic progenitor cells [31,32]. Taken together, these
findings suggest that YAP and TAZ expression are crucial for the development or regeneration of the
cholangiocytic lineage.
Tissue microarrays are increasingly popular for gene expression studies in cancer samples because
they allow the analysis of large numbers of patients on a few slides. However, the use of tissue
microarrays is limited by the very small amount of tumor tissue per patient. This restricts the
evaluation of tissue heterogeneity in different regions of a tumor and may thus produce a false
evaluation. Therefore, we used large tumor samples, which revealed a surprisingly heterogeneous
distribution of YAP and TAZ. This may not have been detected on tissue microarrays. Thus, assessing
YAP and TAZ expression should be done using whole tissue slides or multiple sampling regions within
one tumor, since limited sampling can lead to an undetected positivity.
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Another interesting clinicopathological finding was the association between YAP nuclear positivity
and high proliferative index of tumors in the HCC K19− group. YAP and TAZ bind to TEAD
transcription factors and direct the expression of downstream genes related to cell growth and
cycle progression [33]. However, the prevalence of a high proliferation index in 18 out of 52 K19−
HCC cases with nuclear YAP (Table 2) may be seen as counterintuitive since YAP and TAZ are
associated with invasiveness. Our univariate analysis of Ki-67 in HCC (Table 3) and previous work of
other groups show that Ki-67 positivity has no clear clinical prognostic value in HCC [34,35]. Thus,
the biological function in disease progression of the association between YAP and Ki-67 (proliferation)
remains unknown.
Although YAP and TAZ seem to be critical for tumorigenesis, the significance of nuclear versus
cytoplasmic presence of YAP and TAZ is still poorly understood [36]. Some studies found a nuclear
presence of YAP as a prognostic marker, while others observed comparable results for cytoplasmic
presence [37–40]. Until now, no study investigated YAP or TAZ in the cytoplasm and nucleus within
one tumor. Our results suggest that YAP overexpression in the cytoplasm and nucleus has an important
role in the aggressiveness of HCC. Indeed, a multivariate Cox regression analysis taking into account
the cofounding factors revealed that YAP in the cytoplasm had a significant correlation with poor
prognosis in HCC K19− patients. A reason why the prognostic role of YAP positivity is only trending
in our cohort rather than definitive as indicated in other studies could be because of the more stringent
selection of HCCs in our study [16,41]. We excluded all K19+ cases, which are known to be more
aggressive. A possible explanation for the rather poor prognosis in HCC with only YAP positivity in
the cytoplasm compared to YAP in the nucleus and cytoplasm could be due to the inability to detect
weak nuclear positivity by immunohistochemistry in these cases. The undetectability of nuclear YAP
could explain why HCCs with a poor prognosis were wrongfully included in the group of “YAP only
cytoplasmic positive tumors”, which would lead to a worse prognosis in the YAP-cytoplasmic-positive
group compared to the YAP-nuclear-positive group. On the other hand, cytoplasmic presence of TAZ
does not seem to have an impact on recurrence-free survival or overall survival, while nuclear TAZ is
a very strong predictor of poor prognosis for K19− HCC. Since all cHCC-CCA and CCA were highly
positive for cytoplasmic and nuclear YAP and TAZ, it was not possible to perform a survival analysis
based on the expression of YAP or TAZ in these tumors. In comparison with the other types of primary
liver cancer it was clear that cHCC-CCA had an overall worse prognosis compared to HCC.
In conclusion, we studied the expression profile of YAP and its less studied homolog TAZ.
In contrast to previous work, which mainly examined virally induced HCC, our analysis was
performed on a Caucasian, non-viral-dominant cohort of PLC patients and shows insight into the
clinical relevance of the cellular localization of YAP and TAZ in HCC K19−, HCC K19+, cHCC-CCA,
and CCA cases.
4. Materials and Methods
4.1. Patients and Samples
A retrospective cohort of 141 patients who underwent surgery for primary liver cancer or
cholangiocarcinoma at the University Hospitals in Leuven (Belgium) was included in this study.
After surgery, the resection specimen was taken and fixed in 6% buffered formalin, and multiple
representable sections were taken. The clinicopathological characteristics included the age, sex,
background diseases, prognostic follow-up data, the final pathological diagnosis, tumor size of
the largest nodule, multiplicity, vascular invasion, and the histological grading of the tumor (well,
moderately, poorly). The ethical committee of the University Hospital of Leuven approved this study
(S62171, 30/10/2018). An informed consent was not required in accordance with Belgian Law.
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4.2. Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed paraffin-embedded sections (FFPE) cut
at 4 µm. Antigen epitope retrieval was performed using the DAKO PT Link (Dako, Santa Clara, CA,
USA) in a citrate buffer (pH 6) or Tris-EDTA buffer (pH 9) according to the manufacturer’s instructions.
Blocking of the endogenous peroxidase was achieved by Dual endogenous Enzyme-Blocking Reagent
(Dako, Santa Clara, CA, USA). The slides were subsequently incubated for 30 minutes at room
temperature with primary antibodies for YAP (1/100; Abcam, Cambridge, UK), TAZ (1/100;
Sigma-Aldrich, Saint Louis, MO, USA), K19 (ready-to-use; Dako), and Ki-67 (ready-to-use; Dako). After
incubation of the primary antibody, the slides were incubated with a horseradish-peroxidase-labelled
Envison Flex system (Dako) for 30 minutes at room temperature. Peroxidase activity was detected
with 3.3′-diaminobenzidinen (Dako) as a substrate. All slides were counterstained with Mayer’s
haematoxylin and mounted. Negative and positive controls were included.
The immunoreactivity was evaluated by two independent observers (TR and MVH).
The histoscore (H-score) was calculated semi-quantitatively for YAP and TAZ. Expression of YAP and
TAZ was graded as 0, negative; 1, weak; 2, moderate; or 3, strong; and the percentage of positive
tumor cells was scored separately for the cytoplasm and the nucleus. The possible range of expression
scores was between 0 and 300. Cytoplasmic K19 expression in greater than 5% of the tumor cells
was considered positive. Nuclear Ki-67 staining in more than 5% of the tumor cells in 10 high-power
fields was considered high. We dichotomized the positivity of YAP/TAZ when necessary for survival
analysis. A cut-off of≥10% positivity in the tumour cells was considered positive, which is comparable
to previous similar studies [16,39].
4.3. Statistical Analysis
Statistical analyses were performed using SPSS software version 25 (SPSS inc., Chicago, IL, USA)
and GraphPad Prism version 8.00 for Windows (GraphPad Software, San Diego, CA, USA). Chi-square
test and Fisher’s exact test were used for the analysis of categorical variables. Differences in continuous
variables were investigated using the independent Student’s t-test and analyses of variance (ANOVA).
ANOVA was followed by Tukey’s multiple comparison test. Clinicopathological variables were
dichotomized with respect to their relevance. Disease-free survival (DFS) and overall survival (OS)
figures were generated by using the Kaplan–Meier method. The Cox proportional hazard model was
used to investigate the effects of each parameter on both survivals separately (univariate models)
and combined (multivariate models). The Cox proportional method was also used to determine
the hazard ratios (HRs) and the respective 95% confidence intervals (CIs). Multiple testing was not
performed due to the explorative nature of this experiment. All p-values less than 0.05 were considered
statistically significant.
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Abbreviations
HCC Hepatocellular carcinoma
PLC Primary liver cancer
HBV Hepatitis B virus
HCV Hepatitis C virus
NAFLD Non-alcoholic fatty liver disease
cHCC-CCA Combined hepatocellular–cholangiocarcinoma
CCA Cholangiocarcinoma
K19 Keratin 19
K19+ Keratin 19 positive
K19− Keratin 19 negative
YAP Yes-associated protein 1
WWTR1 WW domain-containing transcription regulator protein 1
TAZ Transcriptional co-activator with PDZ-binding motif
MST1/2 STE20-like protein kinases 1/2
LATS1/2 Large tumor suppressor 1/2
Sav1 Salvador 1
MOB1A/B Mob kinase activator 1A
DFS Disease-free survival
OS Overall survival
ASH Alcoholic steatohepatitis
NASH Nonalcoholic steatohepatitis
PBC Primary biliary cholangitis
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